ArticleJournal of cardiothoracic surgery2026
MicroRNA-425-5p as a diagnostic biomarker and ox-LDL-induced VSMC regulator in atherosclerosis.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs (miRNAs) are key regulators of atherosclerotic (AS) development. This study aimed to evaluate miR-425-5p expression patterns and their clinical relevance in patients with AS.
methods131 patients with AS and 112 controls were enrolled. Serum miR-425-5p and Krüppel-like factor 7 (KLF7) levels were quantified using RT-qPCR. ROC analysis assessed the diagnostic value of miR-425-5p for AS, and logistic regression identified risk factors. An in vitro AS model was established using ox-LDL-stimulated HVSMC cells. Cell viability, apoptosis, inflammatory cytokine secretion, and migration were assessed by CCK-8, flow cytometry, ELISA, and Transwell assays, respectively. Bioinformatics was used to predict the downstream target genes of miR-425-5p, and their targeting bindings were verified by DLR and RIP assays.
resultsmiR-425-5p was significantly upregulated, while KLF7 was downregulated, in serum of AS patients and in ox-LDL-stimulated HVSMCs. Serum miR-425-5p was positively correlated with CIMT, TG, and LDL-C, and negatively correlated with HDL-C. It showed favorable diagnostic performance for AS (85.50% sensitivity, 85.71% specificity) and was identified as an independent risk factor for AS. Moreover, ox-LDL-induced HVSMC dysfunction, including reduced viability, increased apoptosis, elevated migration, and excessive inflammation, was attenuated by miR-425-5p inhibition and further attenuated by KLF7 knockdown.
conclusionsSerum miR-425-5p demonstrates diagnostic potential for AS and correlates with HVSMC proliferation, apoptosis, migration, and inflammatory responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.